Period of remission after treatment with UVA-1 in sclerodermic skin diseases

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 7, 2008, Pages 839-844

  Kroft, E B M ^a   Van De Kerkhof, P C M ^a   Gerritsen, M J P ^a   De Jong, E M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Durometer; Period of remission; Sclerodermic skin disease; UVA 1 phototherapy

Indexed keywords

METHOTREXATE; PREDNISONE; PSORALEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CUTANEOUS PARAMETERS; DOSIMETRY; EOSINOPHILIC FASCIITIS; ERYTHEMA; FATIGUE; FEMALE; FOLLOW UP; HARDNESS; HUMAN; MALE; MORPHEA; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUVA; QUANTITATIVE ANALYSIS; RATING SCALE; REMISSION; SCLERODERMA; SCLEROMYXEDEMA; SCORING SYSTEM; SKIN PIGMENTATION; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME; ULTRAVIOLET THERAPY;

EID: 45449093086     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02576.x     Document Type: Article

References (27)

1. Uziel Y, Feldman BM, Krafchik BR, Yeung RS, Laxer RM. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 2000; 136: 91-95.
2. Seyger MM, van den Hoogen FHMSHU, de Jong EM. A patient with a severe scleroedema diabeticorum, partially responding to low-dose methotrexate. Dermatology 1999; 198: 177-179.
3. Wach F, Ullrich H, Schmitz G, Landthaler M, Hein R. Treatment of severe localized scleroderma by plasmapheresis - report of three cases. Br J Dermatol 1995; 133: 605-609.
4. Czarnecki DB, Taft EH. Generalized morphoea successfully treated with salazopyrine. Acta Derm Venereol 1982; 62: 81-82.
5. Mohrenschlager M, Jung C, Ring J, Abeck D. Effect of penicillin G on corium thickness in linear morphea of childhood: An analysis using ultrasound technique. Pediatr Dermatol 1999; 16: 314-316.
6. Falanga V, Medsger TA Jr. d -penicillamine in the treatment of localized scleroderma. Arch Dermatol 1990; 126: 609-612.
7. Terheyden P, Becker JC, Lurz C, Kahaly GJ, Brocker EB. Treatment of scleromyxoedema with hydroxychloroquine. J Dtsch Dermatol Ges 2003; 1: 30-35.
8. Hunzelmann N, Anders S, Fierlbeck G et al. Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma. J Am Acad Dermatol 1997; 36: 433-435.
9. Dytoc M, Ting PT, Man J, Sawyer D, Fiorillo L. First case series on the use of imiquimod for morphoea. Br J Dermatol 2005; 153: 815-820.
10. Man J, Dytoc MT. Use of imiquimod cream 5% in the treatment of localized morphea. J Cutan Med Surg 2004; 8: 166-169.
11. Ayres S Jr, Mihan R. Is vitamin E involved in the autoimmune mechanism? Cutis 1978; 21: 321-325.
12. Hulshof MM, Pavel S, Breedveld FC, Dijkmans BA, Vermeer BJ. Oral calcitriol as a new therapeutic modality for generalized morphea. Arch Dermatol 1994; 130: 1290-1293.
13. Neuhofer J, Fritsch P. Treatment of localized scleroderma and lichen sclerosus with etretinate. Acta Derm Venereol 1984; 64: 171-174.
14. Strauss RM, Bhushan M, Goodfield MJ. Good response of linear scleroderma in a child to ciclosporin. Br J Dermatol 2004; 150: 790-792.
15. Dawe RS. Ultraviolet A1 phototherapy. Br J Dermatol 2003; 148: 626-637.
16. Humbert P, Dupond JL, Agache P et al. Treatment of scleroderma with oral 1,25-dihydroxyvitamin D3: Evaluation of skin involvement using non-invasive techniques. Results of an open prospective trial. Acta Derm Venereol 1993; 73: 449-451.
17. Seyger MM, van den Hoogen FHBT, de Jong EM. Reliability of two methods to assess morphea: Skin scoring and the use of a durometer. J Am Acad Dermatol 1997; 37: 793-796.
18. Mutzhas MF, Holzle E, Hofmann C, Plewig G. A new apparatus with high radiation energy between 320 and 460 nm: Physical description and dermatological applications. J Invest Dermatol 1981; 76: 42-47.
19. Petersen MJ, Hansen C, Craig S. Ultraviolet A irradiation stimulates collagenase production in cultured human fibroblasts. J Invest Dermatol 1992; 99: 440-444.
20. Gruss C, Reed JA, Altmeyer P, McNutt NS, Kerscher M. Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts. Lancet 1997; 350: 1295-1296.
21. Wlaschek M, Wenk J, Brenneisen P et al. Singlet oxygen is an early intermediate in cytokine-dependent ultraviolet-A induction of interstitial collagenase in human dermal fibroblasts in vitro. FEBS Lett 1997; 413: 239-242.
22. Yin L, Yamauchi R, Tsuji T, Krutmann J, Morita A. The expression of matrix metalloproteinase-1 mRNA induced by ultraviolet A1 (340-400.nm) is phototherapy relevant to the glutathione (GSH) content in skin fibroblasts of systemic sclerosis. J Dermatol 2003; 30: 173-180.
23. Breuckmann F, Pieck C, Kreuter A et.al. Opposing effects of UVA1 phototherapy on the expression of bcl-2 and p53 in atopic dermatitis. Arch Dermatol Res 2001; 293: 178-183.
24. Vishwanath V, Frank KE, Elmets CA, Dauchot PJ, Monnier VM. Glycation of skin collagen in type I diabetes mellitus. Correlation with long-term complications. Diabetes 1986; 35: 916-921.
25. Shulman LE. Diffuse fasciitis with eosinophilia: A new syndrome? Trans Assoc Am Physicians 1975; 88: 70-86.
26. Doyle JA, Ginsburg WW. Eosinophilic fasciitis. Med Clin North Am 1989; 73: 1157-1166.
27. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001; 44: 273-281.